Table 3 Secondary outcomes
Name of study | Outcome | Arginine group | Placebo/control | RR, 95% CI |
|---|---|---|---|---|
Amin et al. [30] | RDS | 48/75 (64) | 51/77 (66) | 0.97 (0.77-1.22) |
Polycarpou et al. [31] | RDS | 31/40 (77.5) | 35/43 (81.4) | 0.95 (0.76-1.19) |
Amin et al. [30] | IVH grade III and IV | 3/75 (4) | 3/77 (4) | 1.03 (0.21-4.93) |
Polycarpou et al. [31] | IVH grade III and IV | 9/40 (22.5) | 12 (27.9) | 0.81 (0.38-1.71) |
Amin et al. [30] | Total PDA | 46/75 (61) | 45/77 (58) | 1.13 (0.59-2.16) |
Amin et al. [30] | PDA treated with indomethacin | 33/75 (44) | 38/77 (49) | 0.89 (0.63-1.25) |
Amin et al. [30] | PDA treated surgically | 15/75 (20) | 13/77 (17) | 1.18 (0.61-2.32) |
Amin et al. [30] | Sepsis | 9/75 (12) | 11/77 (14) | 0.84 (0.37-1.91) |
Amin et al. [30] | Hypotension after 24Â h age | 8/75 (11) | 8/77 (10) | 1.03 (0.37-2.90) |